REMARKS

By the present amendment, Applicants have amended the specification at page 17 and claim 11 to make reference to SEQ ID NO. 1. Also, in claim 11, "glycine" has been replaced with "glutamine" to reflect the sequence identified in the disclosure. It is submitted that the amendments do not introduce any new matter and entry of the amendments are respectfully requested.

In order to comply with the requirements of 37 C.F.R. 1.821-1.825, Applicants are submitting herewith (1) a Sequence Listing in paper form; (2) a Sequence Listing in computer readable form (a 3.5" floppy diskette) in the ASCII format and (3) a statement (set forth below) that the paper form and the computer readable form of the Sequence Listing are the same.

In accordance with the requirements of 37 C.F.R. 1.821-1.825 the undersigned verifies that the paper form of the Sequence Listing and the computer readable form of the Sequence Listing are the same. No new matter has been added.

If any additional fee is due, including a fee for an extension of time, such an extension is hereby requested and the Commissioner is authorized to charge any such fee to Deposit Account No. 02-2095.

Respectfully submitted,

Lauraine Wagter-Lesperance et al.



Patricia Power
Registration No. 51,379

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario
Canada M5H 3Y2

(416) 364-7311

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification

Paragraph beginning at line 24 of page 16 has been amended as follows:

"Antigen" as used herein, refers to any agent to which an animal is exposed and elicits the specified immune response. Suitable antigens for use in the present invention can be of animal, bacterial, viral, synthetic, or other origin. For instance in cows, suitable antigens include but are not limited to ovalbumin, hen egg white lysozyme, human seralbumin, red blood cells from any animal other than the cow; tyrosine - glutamine - alanine – lysine (SEQ ID NO. 1) co-polymer (a synthetic antigen). In choosing suitable antigens for the present invention, the antigens are preferably ones to which the animal is not normally exposed, and preferably one to which they have not been exposed. A person skilled in the art would appreciate that the preferred antigens will depend on the animal species used. Preferably the antigen is either formulated with an Adjuvant or is formulated in to a vaccine.

Sequence Listing page 139 has been inserted into the application.

In the Claims

Claim pages 139-152 have been renumbered as pages 140-153.

Claim 11 has been amended as follows:

11. (Amended) The method according to claim 1, wherein the antigen is selected from the group consisting of hen egg white lysozyme, human serum albumin, tyrosine- [glycine] glutamine-alanine-lysine (SEQ ID NO. 1) co-polymer and ovalbumin.

In the Abstract

Abstract page 153 has been renumbered as page 154.